AMED - Amedisys up 5% as Jefferies sees more appropriate financial guidance

• Amedisys ( NASDAQ: AMED ) is up 5% in Wednesday afternoon trading after a Jefferies analyst said that returning CEO Paul Kusserow said the company will be more conservative with its guidance.
• Brian Tanquilut, who met with management recently, said that they realize that poor share performance in 2022 was infleunced by earnings misses and guidance cuts.
• "As he returns to the CEO seat, Kusserow noted a focus on avoiding a repeat of these earnings shortfalls, which we interpret as an intent to incorporate adequate conservatism into guidance ranges for CY23," Tanquilut wrote.
• He added that the healthcare services provider is also benefitting from an improvement in the labor situation.
• Read why Seeking Alpha contributor Zach Bristow rates Amedisys ( AMED ) a hold.

For further details see: